Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results

October 11, 2022
img: Featured

Conference Call and Webcast Scheduled for Tuesday, November 1

SAN DIEGO, Oct. 11, 2022 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on November 1, 2022.

The schedule for the press release and conference call / webcast is as follows:

• Q3 2022 Press Release:

November 1, 2022 at 4:30 a.m. PT / 7:30 a.m. ET

• Q3 2022 Conference Call: 

November 1, 2022 at 5:00 a.m. PT / 8:00 a.m. ET

• Domestic Dial-In Number:


• International Dial-In Number:


• Conference ID:


The webcast can also be accessed on Neurocrine Biosciences' website under Investors at A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit, and follow the company on LinkedIn. (*in collaboration with AbbVie)

CisionView original content to download multimedia:

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc., Tony Jewell (Media), 858-617-7578,; Todd Tushla (Investors), 858-617-7143,